Novel Simple Organic Compounds for Treating Obesity
Novel small organic compounds derived from fatty acids , for treating obesity by regulating feeding and body weight Experiments in mice showed decreased food consumption and increased activity resulting in decrease in weight Improved cognitive function due to increased Norepinephrine levels There is a clear opportunity for an effective and well-tolerated anti-obesity drug. Our Innovation
Novel derivatives of fatty acids injected into mice caused reduction in2-Arachidonoyl glycerol (2-AG) levels in the hypothalamus causing a decrease in feeding activity, increase in serotonin (5-HT) levels in the hypothalamus causing feeling of satiety and increase in Norepinephrine levels in the hippocampus resulting in improvement in learning. Weight loss continued for 31 days after cessation of treatment and then levelled off. Key Features
Patent on new compounds which are small organic molecules Non toxic Can be delivered orally or by injection Effects resemble beneficial effects of moderate caloric restriction Development Milestones
Continuing studies to determine optimal dosage levels and intervals Toxicology studies The Opportunity
1.1 billion people worldwide are suffering from the health consequences of overconsumption Only two drugs are currently approved for long-treatment of obesity; the lipase inhibitor orlistat and sibutramine. Use of both products has been limited by side effects.
Type of Offer:
« More Healthcare Patents« More Food Science Patents